Prospective follow-up of HIV positive patients with and without access to antiretroviral therapy: Survival and complications;Seguimiento prospectivoe de una población infectada por VIH con y sin posibilidades de terapia anti-retroviral: Impacto en sobrevida y complicaciones

Revista Medica de Chile

Volumn 129, Issue 8, 2001, Pages 886-894

  Wolff R, Marcelo ^a   Diomedi A, Alexis ^a   Morales B, Omar ^a   Bidart H, Teresa ^a   Dabanch P, Jeannette ^a   Bustamante M, Claudia ^a   Northland A, Rebeca ^a  

^a NONE

Author keywords

Antiviral agents; HIV infections; Retroviridae

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CHILE; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MIDDLE AGED; MORTALITY; PROSPECTIVE STUDY; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; ANTI-HIV AGENTS; CASE-CONTROL STUDIES; CHILE; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0035432890     PISSN: 00349887     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. PALELLA FJ, DELANEY KM, MOORMAN AC, LOVELESS MO, FUHRER J, SATTEN GA ET AL. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338: 853-60.
2. HOGG RS, HEATH KV, YIP B, CRAIB KJP, O'SHAUGNESSY MV, SCHECHTER MT ET AL. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA 1998; 279: 450-7.
3. GULICK RM, MELLORS J, HAVLIR D, EVON JJ, GONZÁLEZ C, MCMAHOLL B ET AL. Treatment with indinavir, zidovudine and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997; 337: 734-9.
4. HAMMER SM, SQUIRES KE, HUGHES MD, GRIMES JM, DEMETER LM, CURRIER JS ET AL. A controlled trial of two nucleoside analogs plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997; 337: 725-33.
5. KATZENSTEIN DA, HAMMER SM, HUGHES MD, GUNDACKER H, JACKSON JB ET AL. Relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV - infected adults with 200 to 500 CD4 cells per cubic millimeter. N Engl J Med 1996; 335: 1091-8.
6. SARAVOLATZ LD, WINSLOW DL, COLLINS G, HODGES JS, PETINELLI C, STEIN DS ET AL. Zidovudine alone or in combination with didanoside or zalcitabine in HIV-infected patients with acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. N Engl J Med 1996; 335: 1099-106.
7. KEISER P, KVANLI MB, TURNER D, REISCH J, SMITH JW, NASSAR N ET AL. Protease inhibitor-based therapy is associated with decreased HIV-related health care costs in men treated at a Veterans Administration Hospital. J Acquir Immune Defic Syndr Hum Retrovirol 1999; 20: 28-33.
8. MOORE RD, CHAISSON RE. Natural history of HIV infection in the era of combination antiretroviral therapy. AIDS 1999; 13: 1933-42.
9. WEBER AE, ALAKAWAF R, MONTANER JS, O'SHAUGNESSY MV, HOGG RS. Bitter pill: the current state of antiretroviral care in selected nations around the globe. AIDS 1999; 77: 869-70.
10. FISCHL MA, RICHMAN DD, HANSEN N, COLLIER AC, CAREY JP, HARDLY WD ET AL. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection: a double-blind, placebo-controlled trial. Ann Intern Med 1990; 112: 727-37.
11. STASZEWSKI V, MORALES-RAMÍREZ J, TASKIMA KT, RACHLIS A, SKIEST D, STANFORD J ET AL. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med 1999; 341: 1865-73.
12. SCHNEIDER MME, BORLEFFS JCC, STOLK RP, JASPERS CAJJ, HOEPELMAN AIM. Discontinuation of prophylaxis for Pneumocystis carinii pneumonia in HIV-1 infected patients treated with highly active antiretroviral therapy. Lancet 1999; 353: 201-3.
13. MUSSINI C, PEZZOTTI P, GOVORI A, BORGHI V, ANTINORI A, D'ARMINO MONTEFORTE A ET AL. Discontinuation of primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus type-1 infected patients: the changes in opportunistic prophylaxis study. J Infect Dis 2000; 181: 1635-42.
14. SENDI PP, BUCHER HC, HARR T, CRAIG BA, SCHWIETERT M, PFLUGER D ET AL. Cost effectiveness of highly active therapy in HIV-infected patients. AIDS 1999; 13: 1115-22.
15. FREEBERG KA, LOSINA E, WEINSTEIN MC, PALTIEL AD, COIIEN CJ, SEAGE GR ET AL. The cost effectiveness of combination anti retroviral therapy for HIV disease. N Engl J Med 2001; 344: 824-31.
16. Declaración de Durban: www.Durbandeclaration.org. 24 de marzo de 2001.
17. RHONE SA, HOGG RS, YIP B. SHERLOCK C, CONWAY B, SCHECHTER MT ET AL. Do dual nucleoside regimens have a role in an era of plasma viral load-driven anti retroviral therapy? J Infect Dis 1998; 178: 662-8.
18. ROBINSON M, REED G, CSAKY KG, POLIS MA, WHITCUP SM. Immune recovery uveitis in patients with cytomegalovirus retinitis taking highly active antiretroviral therapy. Am J Ophtalmol 2000; 130: 49-56.
19. Comité Consultivo de SIDA. Sociedad Chilena de Infectología. Pronunciamiento: Terapia antirretroviral. Rev Med Chile 1998; 126: 577-81.